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Abstract
New avenues to modulate the autophagy–lysosomal route of protein clearance have the potential to help treat
several disease states to which the elderly are particularly vulnerable. Two recent papers identified distinct ways
to tap into the lysosomal degradation pathway of autophagy to reduce age-related protein accumulation events.
Shoji-Kawata et al. (Nature 2013;494:201–206) describe a new autophagy-inducing peptide, Tat-Beclin 1, that
enhances the clearance of polyglutamine aggregates related to Huntington’s disease and, interestingly, suppresses
viral and bacterial infections. Savolainen et al. (Neurobiol Dis 2014;68:1–15) describe a prolyl oligopeptidase
inhibitor that reduces a-synuclein species related to Parkinson’s disease and other a-synucleinopathies, and this
inhibitor caused a concomitant increase in autophagic activation markers. Previous studies have also linked the
autophagy–lysosomal pathway to the protective clearing of the Ab peptides of Alzheimer’s disease and tau
species of tauopathies. Enhancing autophagy–lysosomal efficiency may provide a therapeutic avenue for diverse
types of proteinopathies, including the most common neurodegenerative disorders of the elderly.
Introduction
The lysosomal degradation pathway of autophagyis critical for cellular homeostasis, providing efficient
digestion and turnover of cellular components and contrib-
uting to cell health and longevity. The lysosome organelle
contains 50–60 different enzymes responsible for the re-
cycling of cellular constituents and waste, thus employing
several degradation avenues to break down biomolecules,
including proteins, polysaccharides, lipids, and nucleic ac-
ids. Disruption and instability of lysosomes during aging are
factors in pathogenic accumulation events, and modulation
of the autophagy–lysosomal pathway has been identified as
a potential strategy to treat age-related protein accumulation
disorders linked to dementia.1,2 In addition to neurodegen-
erative diseases, the lysosomal degradation pathway of
autophagy represents a therapeutic target for treating met-
abolic, inflammatory, infectious, neoplastic, and muscle
disorders.3–5 Agents that positively influence this single
pathway thereby have the potential to offset numerous dis-
ease states to which the elderly are particularly vulnerable
(results from references 6–20 are summarized in Table 1).
Improving the pathway’s function of protein clearance may
very well impact human health on a global scale.
Eukaryotic cells have two major intracellular protein
degradation pathways, the ubiquitin–proteasome system and
the autophagy–lysosomal route. A growing number of target
identification and drug discovery efforts point to the latter as
a treatment avenue for a broad range of pathologies. The
autophagy–lysosomal pathway has a crucial role in cellular
defense and cytoplasmic homeostasis, exemplified by a
newly identified autophagy-inducing peptide, Tat-Beclin 1.6
The recent report by Shoji-Kawata et al. is of particular note
due to the several disease indications studied. In the report,
the Tat-Beclin 1 peptide was found to protect against
viral infections, decreasing the replication of several viral
pathogens including human immunodeficiency virus (HIV),
and even reducing the mortality rate in mice infected with
the West Nile virus. They also showed that the lysosomal
degradation pathway of autophagy can be induced to defend
against a bacterial infection. Specifically, Tat-Beclin 1 re-
duced the intracellular survival of the bacterium Listeria
monocytogenes that causes listeriosis, a disease that pro-
duces central nervous system (CNS) infections primarily in
the elderly and other at-risk groups (newborns, pregnant
women, adults with weakened immune systems). Tat-Beclin
1 was also found to elicit clearance of small polyglutamine
(polyQ) aggregates. Thus, the autophagy–lysosomal path-
way impacts protein misfolding/accumulation events of
polyQ repeat expansion disorders, Huntington’s disease
being the most prevalent of the neurodegenerative polyQ
disorders.
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Related to the Shoji-Kawata et al. study with regard to the
expanding role of autophagy and lysosomes, the pathway
also targets proteins associated with other neurodegenera-
tive diseases. In fact, four distinct types of protein accu-
mulations found in age-related disorders can be placed on
the list of therapeutic indications linked to the autophagy–
lysosomal clearance pathway. Alzheimer’s disease, Hun-
tington’s disease, tauopathies, and Parkinson’s disease have
the common feature of intracellular protein accumulation
pathology (Alzheimer’s disease also exhibits extracellular
deposition). These proteinopathies are also similar in that
they are generally characterized by the loss of neurons,
synaptic integrity, and cognitive and/or motor ability. Protein
species implicated in the diseases include: (1) pathological
assembly states of Ab42 peptide, (2) mutant huntingtin pro-
tein, (3) tau modifications that lead to paired helical filament
(PHF) formation and neurofibrillary pathology of fronto-
temporal dementia and other tauopathies, and (4) point
mutations in a-synuclein that enhance aggregation and cause
dominant forms of Parkinson’s disease. Interestingly, the
four types of proteins are targeted by a common lysosomal
clearance pathway involving the cysteine protease cathepsin
B (CatB).
CatB was previously shown to degrade Ab42 into smaller,
less pathogenic peptides via carboxy-terminal truncation.7
The study also found that genetic ablation of CatB, by
crossing CatB- / - mice with human amyloid precursor pro-
tein (hAPP) transgenic mice, resulted in increased Ab42 levels
and the worsening of Ab deposition and other Alzheimer-type
pathologies. Correspondingly, Ab deposition in mouse mod-
els of Alzheimer’s disease was significantly reduced when
CatB activity was enhanced by over-expressing the enzyme
through lentiviral delivery7 or by pharmacologically in-
creasing the active form of CatB in neurons.8,9 The latter
utilized Z-phenylalanyl-alanyl-diazomethylketone (PADK), a
cathepsin modulatory compound that selectively enhances
CatB in lysosomes, resulting in decreased intracellular Ab.
The diminished Ab42 levels in PADK-treated transgenic mice
correlated with augmented measures of active CatB, increases
in the truncated Ab38 peptide, decreases in extracellular de-
posits, and reductions in cellular and behavioral disease pa-
rameters. Similar cathepsin modulation, Ab clearance, and
functional benefits resulted when endogenous inhibitors of
lysosomal cysteine proteases were genetically deleted in mice
expressing hAPP with familial Alzheimer’s disease-linked
mutations10,11 or wild-type hAPP.12
The relationship between CatB and the Ab peptide is
similar to the relationship CatB has with other proteins of
proteinopathies, including the link between mutant hun-
tingtin protein and the lysosomal enzyme. Reducing CatB
activity was found to worsen mutant huntingtin protein
toxicity in primary neurons, whereas enhancing CatB ac-
tivity led to autophagy-dependent neuroprotection.13 In a
related Huntington’s disease study that specifically mea-
sured the clearance of a long-lived polyQ protein aggregate,
induction of autophagy decreased the polyQ aggregates and,
as in the other studies, this effect was abrogated by dis-
rupting the activity of lysosomal enzymes.14 In addition to
Alzheimer’s disease and Huntington’s disease, the CatB
relationship extends to the tau protein of tauopathies. Pre-
vious studies showed that CatB inhibition and lysosomal
disruption cause an increase in both phosphorylated tau
levels and intracellular PHF-tau aggregates in hippocampal
tissue.15,16 Correspondingly, reductions in phosphorylated
tau, PHF-tau aggregates, and tau-related pathology occurred
when CatB was enhanced with the modulatory compound
PADK.16,17
Aggregated a-synuclein in dementia with Lewy bodies,
Parkinson’s disease, and other a-synucleinopathies is the
fourth type of age-related protein accumulation event in-
cluded as being targeted by the autophagy–lysosomal
pathway. In recent studies, a-synuclein was localized to the
lysosomal degradation pathway and, similar to Ab and
phosphorylated tau, inhibition of cathepsin proteases caused
an increase in a-synuclein aggregates.18,19
Finally, a more recent study by Savolainen et al.20 dis-
covered a link between enhancement of the autophagic
pathway and accelerated clearance of a-synuclein. The study
identified a compound (KYP-2047) that reduces the amount
of aggregated a-synuclein in cellular models and transgenic
mice. KYP-2047 positively modulates the lysosomal deg-
radation pathway of autophagy by inhibiting prolyl oligo-
peptidase, a mechanism distinct from the way Tat-Beclin 1
induces autophagic clearance of polyQ aggregates. Tat-Beclin
1 contains amino acids 267–284 of Beclin 1, an essential
autophagy protein in the class III phosphatidylinositol-3-OH
kinase complex. By mimicking Beclin 1, the Tat-Beclin 1
peptide blocks HIV-1 Nef’s ability to be an anti-autophagic
maturation factor through its interaction with Beclin 1. The
recent reports indicate that different mechanistic routes
can promote the autophagy–lysosomal pathway to enhance
protein clearance.
Table 1. Effects on Health Challenges of the Elderly When the Autophagic–Lysosomal Route
for Protein Clearance Is Enhanced Versus Disrupted
Health challenge
Effect of enhancing the lysosomal
degradation pathway of autophagy
Effect of disrupting lysosomal
enzyme activity
Viral infection Reduced mortality of infected mice —
Bacterial infection Reduced intracellular survival —
PolyQ aggregates Clearance of polyQ aggregates Long-lived polyQ aggregates
Mutant huntingtin protein Neuroprotection Increased toxicity
Intracellular Ab Reduced Ab levels Increased Ab levels
Extracellular Ab Reduced Ab deposits Increased Ab deposition
PHF-tau Reduced PHF-tau Increased PHF-tau
a-synuclein aggregates Reduced a-synuclein Increased a-synuclein aggregates
PolyQ, polyglutamine; PHF, paired helical filament.
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The autophagy–lysosomal route for protein clearance
influences a wide range of disease states, a range that has
been further broadened by recent studies. In addition to
reducing serious infections commonly found in the elderly,
enhancing protein clearance efficiency in cells has the po-
tential to protect against the most common nervous system
disorders of the elderly. Over 400 million baby boomers are
contemplating the imbalances between protein production
and protein clearance that increase their risk for protein
accumulation diseases as they age. A single pathway that
can target multiple types of proteinopathies provides an
optimistic strategy for extending the healthy life span of the
aging human population.
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